Peroxisome proliferator-activated receptor-γ 34C>G polymorphism and colorectal cancer risk: A meta-analysis

World Journal of Gastroenterology

Volumn 16, Issue 17, 2010, Pages 2170-2175

  Lu, Yong Liang ^a   Li, Gai Ling ^b   Huang, Hui Lian ^c   Zhong, Jing ^c   Dai, Li Cheng ^c  

^a HUZHOU UNIVERSITY   (China)

^b SIP Healo and Halo Life Science Research Center   (China)

^c HUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Colorectal cancer; Meta analysis; Peroxisome proliferator activated receptor ; Polymorphism

Indexed keywords

CYTOSINE; GLYCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW;

EID: 77952513134     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i17.2170     Document Type: Article

References (21)

1. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006; 119: 297-303
2. Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, Hebert JR. The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis 2005; 26: 579-585
3. Sieg A, Friedrich K. Perspectives of colorectal cancer screening in Germany 2009. World J Gastrointest Endosc 2009; 1: 12-16
4. Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, Akasaka S, Ishikawa H, Tokudome S. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. Cancer Sci 2005; 96: 507-512
5. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560-3566
6. Murtaugh MA, Ma KN, Caan BJ, Sweeney C, Wolff R, Samowitz WS, Potter JD, Slattery ML. Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1224-1229
7. Koh WP, Yuan JM, Van Den Berg D, Ingles SA, Yu MC. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis 2006; 27: 1797-1802
8. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1126-1131
9. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris ACh, Patsouris E, Bramis J, Gazouli M. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006; 12: 5037-5043
10. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H, Nexø BA, Raaschou-Nielsen O, Andersen PS, Overvad K, Tjønneland A. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007; 624: 88-100
11. O'Morain C, Qasim A. Concept of chemoprevention in colorectal cancer. World J Gastrointest Oncol 2009; 1: 21-25
12. Sun L, Guan YS, Pan WM, Luo ZM, Wei JH, Zhao L, Wu H. Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection. World J Gastrointest Oncol 2009; 1: 55-61
13. Tejpar S, Van Cutsem E. Molecular and genetic defects in colorectal tumorigenesis. Best Pract Res Clin Gastroenterol 2002; 16: 171-185
14. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 2003; 253: 141-149
15. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-429
16. Theocharis S, Margeli A, Vielh P, Kouraklis G. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 2004; 30: 545-554
17. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361-367
18. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-664
19. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631-2646
20. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C. Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet 2000; 37: 410-414
21. Zambirinis CP, Theodoropoulos G, Gazouli M. Undefined familial colorectal cancer. World J Gastrointest Oncol 2009; 1: 12-20